key: cord-0800294-vggqpydh
authors: de Vries, Judith J.; Visser, Chantal; Geers, Lotte; Slotman, Johan A.; van Kleef, Nadine D.; Maas, Coen; Bax, Hannelore I.; Miedema, Jelle R.; van Gorp, Eric C. M.; Goeijenbier, Marco; van den Akker, Johannes P. C.; Endeman, Henrik; Rijken, Dingeman C.; Kruip, Marieke J. H. A.; de Maat, Moniek P. M.
title: Altered fibrin network structure and fibrinolysis in intensive care unit patients with COVID‐19, not entirely explaining the increased risk of thrombosis
date: 2022-04-01
journal: J Thromb Haemost
DOI: 10.1111/jth.15708
sha: 441fff56eb4585ebff07ab0516470948e50a5919
doc_id: 800294
cord_uid: vggqpydh

BACKGROUND: Severe acute respiratory syndrome coronavirus 2 infection is associated with an increased incidence of thrombosis. OBJECTIVES: By studying the fibrin network structure of coronavirus disease 2019 (COVID‐19) patients, we aimed to unravel pathophysiological mechanisms that contribute to this increased risk of thrombosis. This may contribute to optimal prevention and treatment of COVID‐19 related thrombosis. PATIENTS/METHODS: In this case‐control study, we collected plasma samples from intensive care unit (ICU) patients with COVID‐19, with and without confirmed thrombosis, between April and December 2020. Additionally, we collected plasma from COVID‐19 patients admitted to general wards without thrombosis, from ICU patients with pneumococcal infection, and from healthy controls. Fibrin fiber diameters and fibrin network density were quantified in plasma clots imaged with stimulated emission depletion microscopy and confocal microscopy. Finally, we determined the sensitivity to fibrinolysis. RESULTS: COVID‐19 ICU patients (n = 37) and ICU patients with pneumococcal disease (n = 7) showed significantly higher fibrin densities and longer plasma clot lysis times than healthy controls (n = 7). No differences were observed between COVID‐19 ICU patients with and without thrombosis, or ICU patients with pneumococcal infection. At a second time point, after diagnosis of thrombosis or at a similar time point in patients without thrombosis, we observed thicker fibers and longer lysis times in COVID‐19 ICU patients with thrombosis (n = 19) than in COVID‐19 ICU patients without thrombosis (n = 18). CONCLUSIONS: Our results suggest that severe COVID‐19 is associated with a changed fibrin network structure and decreased susceptibility to fibrinolysis. Because these changes were not exclusive to COVID‐19 patients, they may not explain the increased thrombosis risk.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

is the cause of coronavirus disease 2019 (COVID- 19) , currently causing a global pandemic. SARS-CoV-2 mainly targets the human respiratory tract, causing flulike symptoms ranging from coughing to acute respiratory distress syndrome, requiring mechanical ventilation. Furthermore, COVID-19 patients show an increased risk of thrombotic events. 1, 2 The incidence of these thrombotic events in COVID-19 intensive care unit (ICU) patients is higher than in ICU patients in general or in ICU patients with influenza. 3, 4 This observation suggests that besides ICU admission, additional prothrombotic factors must play a role in the increased incidence of thrombotic complications in COVID-19 patients.

Characteristics of thrombi are largely influenced by properties of the fibrin network (e.g., fiber thickness, fiber density). The fibrin network properties are determined by many factors, such as variations in the fibrinogen molecule, fibrinogen concentration, or environmental factors such as inflammation. 5, 6 Fibrinolysis, the timely removal of fibrin, is largely affected by the structure of the fibrin network 7 and the level of fibrinolysis inhibitors, such as plasminogen activator inhibitor 1 (PAI-1). 8 Therefore, an altered fibrin network structure (denser, prothrombotic) and decreased susceptibility to fibrinolysis could contribute to the increased risk of thrombosis in COVID-19 patients. By studying the fibrin network structure and fibrinolysis of plasma clots from COVID-19 patients, we aimed to unravel pathophysiological mechanisms that contribute to this increased risk of thrombosis. This knowledge may contribute to optimal prevention and treatment of COVID-19 related thrombosis. Results: COVID-19 ICU patients (n = 37) and ICU patients with pneumococcal disease (n = 7) showed significantly higher fibrin densities and longer plasma clot lysis times than healthy controls (n = 7). No differences were observed between COVID-19 ICU patients with and without thrombosis, or ICU patients with pneumococcal infection. At a second time point, after diagnosis of thrombosis or at a similar time point in patients without thrombosis, we observed thicker fibers and longer lysis times in COVID-19 ICU patients with thrombosis (n = 19) than in COVID-19 ICU patients without thrombosis (n = 18).

Our results suggest that severe COVID-19 is associated with a changed fibrin network structure and decreased susceptibility to fibrinolysis. Because these changes were not exclusive to COVID-19 patients, they may not explain the increased thrombosis risk.

COVID-19, fibrin, fibrinolysis, microscopy, thrombosis

• COVID-19 is associated with an increased risk of thrombosis, especially in ICU patients.

• Fibrin network in COVID-19 ICU patients is denser and less prone to lysis than healthy controls. METC-2020-0758). We obtained written informed consent from each healthy control and ICU patient with pneumococcal infection.

An opt-out procedure was in place for the COVID-19 ward and ICU patients.

Blood from all subjects was collected into 3.2% trisodium citrate tubes (9:1 v/v, Becton Dickinson) and centrifuged 15 min at 2500g at room temperature, followed by 20 000g for 10 min. The obtained platelet-poor plasma was stored in aliquots at −80°C until thawed at 37°C immediately before use. Fibrinogen levels were measured using the Clauss assay (Thrombin Reagent, Siemens Healthineers), factor VIII (FVIII) levels using a one-stage clotting assay and FXIII levels with a chromogenic assay using the Berichrom FXIII kit (Siemens Healthineers). In addition, levels of D-dimer (Siemens Healthineers) and anti-Xa (Werfen) were routinely measured. All parameters were measured on the Sysmex Values above the standard of the ELISA were given the maximum value of the standard (40 ng/ml).

To study the properties of the fibrin network, clots were made from 

Plasma clot lysis time was measured to investigate the susceptibility of plasma clots to fibrinolysis, as described in Talens et al. 14 In short, platelet-poor plasma was mixed with tissue factor, CaCl 2 , tissue type plasminogen activator, and phospholipids. Clot turbidity was measured at 405 nm after which clot lysis times were determined using the clot lysis analysis app as described by Longstaff et al. 15 In addition, the difference between the maximum absorbance and baseline absorbance was measured (turbidity change).

Normally distributed data were shown as mean ± standard deviation, not-normally distributed data as median [25th-75th percentile]

and categorical data as n (%). To test for differences between multiple groups, one-way ANOVA (normally distributed data), Kruskal-Wallis test (not-normally distributed data), or χ 2 (categorical data) was used with post hoc Tukey tests. Changes between COVID-19 ICU patients with and without confirmed thrombosis at the second time point were assessed using independent Student t-test (normally distributed data) or Mann-Whitney U test (not-normally distributed data). Changes in variables over time were evaluated using the paired Student t-test (normally distributed data) or Wilcoxon signed-rank test (not-normally distributed data). One-way analysis of covariance was used to assess the effect of COVID-19 disease state (independent variable) on clot characteristics (dependent variables) while adjusting for fibrinogen level. Not-normally distributed variables were log-transformed before using them as dependent variable in the one-way analysis of covariance. We used pairwise deletion in case of missing data. Statistical analyses were performed using IBM SPSS Statistics v25 (IBM) and GraphPad Prism version 8.2.1 (GraphPad Software). 

Representative STED and confocal images of clots prepared from plasma obtained at the first time point of the different groups are shown in Figure 1 . Fiber diameter was similar in the different groups ( Figure 2 ). Fibrin network density was significantly higher in ICU patients with pneumococcal infection, COVID-19 ward patients, and COVID-19 ICU patients without thrombosis compared with healthy controls. Fibrin network density was significantly lower in COVID-19 ICU patients with thrombosis than in ICU patients with pneumococcal infection (Figure 2 ). Turbidity change measured in the fibrinolysis assay was significantly higher in all ICU patient groups than in healthy controls ( Figure 2 ). Adjustment for fibrinogen levels in the statistical analyses did not change these results (Table S1 ).

Clot lysis time was significantly longer in COVID-19 ICU patients with and without thrombosis and ICU patients with pneumococcal infection than in healthy controls, regardless of fibrinogen levels ( Figure 2 and Table S1 ). Interestingly, in the clot lysis assay, no fibrinolysis was observed in 26% (5/ 

In plasma samples collected at the first time point, we did not observe any significant differences in levels of coagulation factors between COVID-19 ICU patients who did and did not develop thrombosis. In plasma samples collected after diagnosis of thrombosis (or at similar time points in patients without confirmed thrombosis), we observed significantly higher levels of fibrinogen, D-dimer, and PAI-1 in patients with confirmed thrombosis than in patients without confirmed thrombosis (Table S3) . Anti-Xa levels were significantly higher in patients with confirmed thrombosis than in patients without confirmed thrombosis, reflecting anticoagulant treatment. 

FVIII levels significantly increased over time in COVID-19 ICU patients with thrombosis (Table S3 ). Clot lysis time significantly decreased over time in patients without confirmed thrombosis. There were no other significant changes in coagulation factors or fibrin network characteristics over time.

Our study revealed that fibrin network structure and susceptibility to lysis were altered in COVID-19 ward and ICU patients compared with healthy controls. A denser fibrin network and decreased susceptibility to fibrinolysis are found in patients with thrombotic disorders 7 and could therefore contribute to the increased risk of thrombosis in COVID-19 patients. However, no significant differences in fibrin structure and fibrinolysis were seen in COVID-19

ICU patients compared with ICU patients with pneumococcal infection without COVID-19. These findings suggest that the observed changes in fibrin network structure and susceptibility to lysis are not caused explicitly by SARS-CoV-2 but might be a more common observation in patients with severe infectious disease involving a high immune response. Therefore, our study does not explain the reported increased risk of thrombosis in COVID-19 ICU patients compared with other ICU patients, 3, 4 but additional pathophysiological mechanisms specific to COVID-19 must be present. 16 In another recent study, clots of critically ill COVID-19 patients were shown Finally, we used platelet-poor plasma in our study. It should be noted that cells, such as red blood cells and platelets, have considerable effects on thrombus properties and may also contribute to thrombosis in COVID-19 patients.

Our results suggest that SARS-CoV-2 infection is associated with an altered fibrin network structure and decreased clot susceptibility to fibrinolysis. Because these changes were not exclusive to COVID-19 patients, they might not entirely explain the increased thrombosis risk observed in COVID-19 patients.

The authors thank Debby Priem-Visser, Aarazo Barakzie, and the technicians of the hemostasis laboratory for their excellent technical assistance. Furthermore, the authors thank all contributors from the F I G U R E 3 Characteristics of clots formed from plasma obtained after diagnosis of thrombosis in COVID-19 ICU patients (+) or at similar time points for COVID-19 ICU patients without confirmed thrombosis (-). *p < .05; **p < .01; ***p < .001. COVID-19, coronavirus disease 2019; ICU, intensive care unit

has received unrestricted grants paid to the department for research outside this work from Bayer and Daiichi Sankyo and has received a speaker

Conceptualization, investigation, formal analysis, visualization, writing -original Draft. Chantal Visser: Conceptualization, investigation, writing -original draft. Lotte Geers: Investigation, writing -original draft. Johan A. Slotman: Methodology, software, writing -review & editing. Nadine D. van Kleef: Investigation, writing -review & editing. Coen Maas: Methodology, resources, writing -review & editing. Hannelore I. Bax: Resources, writing -review & editing. Jelle R. Miedema: Resources, writing -review & editing

Conceptualization, writing -review & editing

Resources, writing -review & editing. Johannes P. C. van den Akker: Resources, writing -review & editing. Henrik Endeman: Conceptualization, resources, writing -review & editing

Rijken: Methodology, supervision, writing -review & editing

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Incidence of venous thromboembolism in hospitalized patients with COVID-19

The impact of deep vein thrombosis in critically ill patients: a meta-analysis of major clinical outcomes

Risk of thrombotic complications in influenza versus COVID-19 hospitalized patients

Effects of posttranslational modifications of fibrinogen on clot formation, clot structure, and fibrinolysis: a systematic review

Fibrin formation, structure and properties

Fibrinogen and fibrin: an illustrated review

Basic mechanisms and regulation of fibrinolysis

Caging the dragon: research approach to COVID-19-related thrombosis

Biological variation of hemostasis variables in thrombosis and bleeding: consequences for performance specifications

NIH image to ImageJ: 25 years of image analysis

Computing local thickness of 3D structure with

Quantification of bone microarchitecture with the structure model index

Biological variation in tPA-induced plasma clot lysis time

Development of Shiny app tools to simplify and standardize the analysis of hemostasis assay data: communication from the SSC of the ISTH

Proposal of the definition for COVID-19-associated coagulopathy

Altered fibrin clot structure and dysregulated fibrinolysis contribute to thrombosis risk in severe COVID-19

The emerging threat of (micro) thrombosis in COVID-19 and its therapeutic implications

Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases

Effect of enoxaparin on plasma fibrin clot properties and fibrin structure in patients with acute pulmonary embolism

Antithrombinindependent effects of heparins on fibrin clot nanostructure

Unfractionated and low molecular weight heparin affect fibrin structure and angiogenesis in vitro

Mechanisms of thrombosis and cardiovascular complications in COVID-19

In vitro hypercoagulability and ongoing in vivo activation of coagulation and fibrinolysis in COVID-19 patients on anticoagulation

Additional supporting information may be found in the online version of the article at the publisher's website.How to cite this article: de Vries JJ, Visser C, Geers L, et al.